Overview
CRO and INJ rarely move in perfect sync. Today’s print ($1,856.75/$5.01) and 24h leaders (Injective) help frame which side currently carries relative strength.
Quick winners
Full comparison
| Metric | CRO | INJ |
|---|---|---|
| Price | $1,856.75 | $5.01 |
| Market Cap | $2.58B | $490.41M |
| FDV | — | — |
| Volume 24h | $3.03M | $2.77M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 37.00 | 99.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +3.64% | +5.97% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | CRO | INJ |
|---|---|---|
| 1H | — | — |
| 24H | -0.60% | +2.04% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | CRO | INJ |
|---|---|---|
| RSI | 49.02 | 49.29 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 67.35 | 0.29 |
| ADX | 21.33 | 12.19 |
| Support | 1,827.82 | 4.91 |
| Resistance | 1,960.30 | 5.07 |
| Trend | bearish | neutral |
| Momentum | 67.00 | — |
| Signal | neutral | neutral |
Automatic technical analysis
Technically, CRO shows RSI 49.02 with trend bias bearish, while Injective sits at RSI 49.29 (neutral). Divergences between momentum and price should be confirmed on higher timeframes.
Fundamentals
| Metric | CRO | INJ |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | — | 0.00 |
| Github activity | — | 118.00 |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
CRO
Injective
Pros and cons
Pros of CRO
- Composite PEPS readings for CRO can surface clearer module agreement during trend phases.
- CRO often anchors narratives that attract sustained media and analyst coverage.
Cons of CRO
- Large-cap status for CRO can mean slower percentage upside versus high-beta alternatives.
- When dominance narratives fade, CRO can lag hotter rotation names.
- Crowded positioning around CRO sometimes amplifies squeeze or flush risk.
Pros of Injective
- Active volume bursts on INJ sometimes precede sharper tactical moves.
- Narrative optionality around Injective can reprice quickly when catalysts appear.
- Injective can offer higher relative beta when market attention rotates toward its niche.
- Diversifying versus CRO with Injective can change portfolio factor exposure.
Cons of Injective
- Weaker market-cap standing may leave Injective more exposed to liquidity droughts.
- Trend failures on Injective often travel faster than on more established assets.
- Higher volatility on INJ cuts both ways and demands stricter risk limits.
Which looks stronger right now?
On the latest snapshot, market-cap leadership belongs to CRO, while short-term performance leans toward Injective. That mix suggests relative strength can flip quickly, so size risk accordingly.
AI summary
This AI-assisted summary starts from live PEPS fields. CRO holds market-cap $2.58B and rank #37; Injective shows $490.41M and #99. Where liquidity and flow matter, watch CRO. Where durability matters, watch CRO. AI composite scores (57.90/47.20) compress those tensions into a single lens. In probabilistic terms, the side winning more columns may have a nearer-term edge, but tails remain fat. Revisit after the next hourly refresh.
FAQ
Which is better, CRO or Injective?
“Better” depends on horizon and risk. CRO leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, CRO or INJ?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both CRO and Injective.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. CRO currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.